Twist Bioscience officer sells shares to cover RSU taxes

Twist Bioscience Corp officer Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, reported a sale of 1,070 shares of common stock on 2026-08-03 at $85.3212 per share.

Rhea-AI Filing Summary

Twist Bioscience Corp officer Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, reported a sale of 1,070 shares of common stock on 2026-08-03 at $85.3212 per share. According to the footnote, this mandated "sell to cover" transaction funded tax withholding on vesting Restricted Stock Units and was not a discretionary trade. After the sale, Cho directly held 104,071 shares of common stock.

Insider Trade Summary

Net Seller: 1,070 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 1,070 shs ($91K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,070	$85.3212	$91K

Holdings After Transaction: Common Stock — 104,071 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Key Figures

Shares sold: 1,070 shares Sale price: $85.3212 per share Shares held after: 104,071 shares +1 more

4 metrics

Shares sold 1,070 shares Common stock sold on 2026-08-03 in tax-related sell-to-cover transaction

Sale price $85.3212 per share Reported transaction price for the 1,070 shares of common stock

Shares held after 104,071 shares Direct holdings of Dennis Cho following the reported sale

Net shares sold 1,070 shares Net share change across all reported transactions in this Form 4

Key Terms

sell to cover, Restricted Stock Units, equity incentive plans, tax withholding obligations

4 terms

sell to cover financial

"funded by a "sell to cover" transaction and do not represent discretionary"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

Restricted Stock Units financial

"tax withholding obligations in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

equity incentive plans financial

"Issuer's election under its equity incentive plans to require the satisfaction"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

tax withholding obligations financial

"shares required to be sold by the Reporting Person to cover tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dennis Cho report at Twist Bioscience (TWST)?

Dennis Cho reported selling 1,070 shares of Twist Bioscience common stock at $85.3212 per share on 2026-08-03. The sale was tied to tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans.

Was Dennis Cho’s share sale in TWST discretionary?

The filing states the sale was not discretionary. Shares were sold under a mandated "sell to cover" arrangement to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units, pursuant to Twist Bioscience’s equity incentive plan election.

How many Twist Bioscience (TWST) shares does Dennis Cho hold after this Form 4?

After the reported transaction, Dennis Cho directly held 104,071 shares of Twist Bioscience common stock. This figure reflects his holdings following the sale of 1,070 shares used to cover tax withholding obligations from RSU vesting.

What price was received in Dennis Cho’s Twist Bioscience (TWST) share sale?

The reported sale price was $85.3212 per share for 1,070 shares of Twist Bioscience common stock. The filing identifies this as a per-share transaction price in connection with a tax-related sell-to-cover transaction for RSU vesting.

Did Dennis Cho’s TWST transaction occur under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox was not affirmed, and the footnote instead explains the sale was mandated by the company’s equity plan as a sell-to-cover tax withholding transaction, rather than a pre-arranged trading plan.

What role does Dennis Cho hold at Twist Bioscience (TWST)?

Dennis Cho is identified as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp. His Form 4 reflects a tax-related sell-to-cover sale of company shares connected to the vesting of Restricted Stock Units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:05 PM Accepted by SEC EDGAR 08/05/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S		1,070(1)	D	$85.3212	104,071	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)